The pharmacokinetics of [3H]‐vincristine in man
- 1 October 1977
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 22 (4) , 430-438
- https://doi.org/10.1002/cpt1977224430
Abstract
The pharmacokinetics, metabolism, and excretion of aromatically labeled tritiated vincristine (VCR) was examined in 4 patients. Clearance of radioactivity from the blood was triphasic with half-life tV2 values of 0.85, 7.4, and 164 min. The initial phases probably represent distribution and binding to formed blood elements which exceeded 50% of the administered dose by 20 min. Excretion of radioactivity was principally fecal, with 33% recovered in the feces by 24 hr and 69% by 72 hr. Considerably less radioactivity (12%) was excreted in the urine over the 72-hr period. Approximately 40% of fecally excreted and 46% of urinary excreted radiolabel represented metabolites, which suggests that at least 34% of the VCR dose was excreted as metabolites. Plasma metabolites represented from less than 1 % to 30% or more of radioactivity in plasma. Ultraviolet spectral analysis of all metabolites revealed preservation of the intact VCR dimer, which suggests that metabolism involves alteration of side groups.This publication has 1 reference indexed in Scilit:
- Kinetics of the Effect of Vincristine Sulfate on the Reproductive Integrity of Proliferating Cultured Leukemia L1210 CellsExperimental Biology and Medicine, 1968